Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC)

Axel Grothey(Campbell Clinic), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), T. Buechele, Karsten Ridwelski(University Hospital Magdeburg), Albrecht Kretzschmar(Roche (Switzerland)), M.R. Clemens, Hendrik Kroening, Peter Reichardt(Helios Hospital Berlin-Buch)
European Journal of Cancer
April 1, 2001
10.1016/s0959-8049(01)81446-5
Cited by 57

Related Papers

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
|New England Journal of Medicine|2018|1.1k